INDONESIA

South-East Asia Region

OTHERS

Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)

Insufficient data
0

Insufficient data
no cases

00.1

Very low PP

00.1

Very low PP

0.11.0

020

0.11.0

020

1.010

2040

1.010

2040

>85

4060

>85

4060

6080

6080

PF-RATIO

Based on 2012 reported data

PP

no cases

80100
Based on 2012 reported data

80100

I. Epidemiological profile
High transmission (>1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria free (0 cases)
Total

Insufficient data

Insufficient data
0

PP

Population

Proportion of cases
PF-RATIO
due
to P.falciparum

PR

2014

Parasites and vectors

30000000
36500000
188000000
254500000

12
14
74

Major plasmodium species: P.falciparum (57%), P.vivax (43%)

Major anopheles species:
An. sundaicus, An. balabacensis, An. maculatus, An. farauti, An. subpictus, An. subpictus
Programme phase:
Control
Reported confirmed cases:
252027 Estimated cases, 2013: [32000005300000]
Reported confirmed cases at community level:
0
Reported deaths:
64 Estimated deaths, 2013:
[54012000]

II. Intervention policies and strategies

Intervention Policies/strategies

Yes/No Adopted

ITN
ITNs/LLINs distributed free of charge
Yes
2004

ITNs/LLINs distributed to all age groups
Yes
2004
IRS
IRS is recommended
Yes
1959

DDT is authorized for IRS
No

Larval control Use of larval control recommended

Yes
1990
IPT
IPT used to prevent malaria during pregnancy
N/A

Diagnosis
Patients of all ages should receive diagnostic test
Yes
2007

Malaria diagnosis is free of charge in the public sector
Yes
1959
Treatment ACT is free for all ages in public sector
Yes
2004

Sale of oral artemisinin-based monotherapies
Never allowed 2010

Single dose of primaquine is used as gametocidal medicine for P.falciparum Yes 2004

Primaquine is used for radical treatment of P.vivax
Yes 2004

G6PD test is a requirement before treatment with primaquine
No

Directly observed treatment with primaquine is undertaken
No

System for monitoring of adverse reactions to antimalarials exists
No

Surveillance ACD for case investigation (reactive)

Yes
1965

ACD of febrile cases at community level (pro-active)
Yes
1965

Mass screening is undertaken
Yes
1965
Uncomplicated P.falciparum cases routinely admitted
Yes
1990
Uncomplicated P.vivax cases routinely admitted
Yes
1990

USAID/PMI

WHO/UNICEF

Source: DHS 2007

Cases per 1000

100
80
60
40
20
0

Management and other costs

Source: DHS 2012

Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
Diagnostics

2000 2001 2002 2003 2004 2005 2006

2007 2008 2009 2010 2011 2012 2013 2014
ITNs

Suspected cases tested

Antimalarials distributed vs reported cases
Insecticide & spraying materials
<5 with fever with finger/heel stick (survey)
ACTs distributed vs reported P. f. cases
Primaquine distributed vs reported P. v. cases
ACTs as % of all antimalarials received by <5 (survey)

All ages who slept under an ITN (survey)

At high risk protected with IRS

At high risk protected with ITNs

All ages who slept under an ITN (survey)
Cases
Households
withtracked
at least one ITN
At high risk protected with IRS Points
At high risk protected with IRS
Source: DHS 2003, DHS 2007, DHS 2012
Tests (%)

Test positivity

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

100
80
60
40
20
0

Reporting completeness

Suspected cases tested

<5 with fever with finger/heel stick (survey)
ACTs as % of all antimalarials received by <5
Primaquine distributed vs reported P.v cases points
Primaquine distributed vs reported P.v cases
ACTs distributed vs reported P.f cases points
ACTs distributed vs reported P.f cases
distributed
reported
cases 2010
points 2011 2012 2013 2014
2000 2001 2002 2003 2004Antimalarials
2005 2006
2007 vs2008
2009
distributedrate
vs reported cases RDT positivity rate
Parasite prevalence (survey) Antimalarials
Slide positivity

Estimated cases detected - top

ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

ABER (microscopy & RDT)

Cases (all species)

Funding source(s): Government,

Global Fund, WHO, UNICEF

Cases tested and treated in public sector

% fever cases <5 seeking treatment at public HF (survey)

10
8
6
4
2
0

Pie chart includes 100%

of total contributions

Others

Cases (%)

Population (%)
(%)

Organophosphate Species/complex tested

No
An. subpictus s.l., An. sundaicus
s.l., other

Insecticides & spray materials

ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and evaluation
Human resources & technical assistance
Management and other costs

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

V. Impact

Pyrethroid DDT Carbamate

Yes
No
Yes

Financing by intervention in 2014

ITN and IRS coverage

Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria budget (USD)

At high risk protected with ITNs

Households with at least one ITN

100
80
60
40
20
0

Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
Year
20112014

Cases (P. vivax)

Malaria admissions and deaths

5
4
3
2
1
0

500 000
400 000
300 000
200 000
100 000
0

Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

Admissions (all species)

Deaths (all species)

1000
800
600
400
200
0

Deaths

World Bank

IV. Coverage
100
80
60
40
20
0

Medicine
Year
Min Median
Max
Follow-up No. of studies Species

Sources of financing

Global Fund

Adopted

DHA-PP+PQ
2008
QN+D+PQ 2004
AM; AS; QN
2004
AS+AQ; DHA-PP+PQ(14d)
2008
0.25 mg/kg (14 d)
P.f + all species (Combo).

Therapeutic efficacy tests (clinical and parasitological failure, %)

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

Government

Medicine

First-line treatment of unconfirmed malaria

First-line treatment of P.falciparum
Treatment failure of P.falciparum
Treatment of severe malaria
Treatment of P.vivax
Dosage of primaquine for radical treatment of P.vivax
Type of RDT used

Admissions

60
48
36
24
12
0

ABER (%)

Contribution (US$m)

III. Financing

Antimalaria treatment policy

Admissions (P. vivax)

Deaths (P. vivax)

Impact: Insufficiently consistent data to assess trends

Aber (microscopy
& RDT)
Cases
(p.vivax) points

Admissions (P.vivax) points

Cases (p.vivax)

Admissions (P.vivax)

Cases (all species) points

Admissions (all species) points

Cases (all species)

Admissions (all species)

Deaths (P.vivax) points

Deaths (P.vivax)

WORLD MALARIADeaths
REPORT
2015
(all species) points
Deaths (all species)

127